

## Corporate Fact Sheet

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody technologies.

## Company Highlights

- Emerging leader in developing immuno-oncology therapeutics
- Pipeline comprising ten differentiated clinical-stage product candidates
- Leading multispecific antibody technology platforms, with seven DART® molecules in clinic
- Fully-integrated mAb-based development capabilities, including GMP manufacturing
- Collaborations with Incyte, Janssen, Servier, Pfizer and Boehringer Ingelheim
- Experienced management team and highly collaborative corporate culture

## Pipeline

Program (Target)	Indication	Pre-IND	Phase 1	Phase 2	Phase 3	Collaborator
<b>ONCOLOGY</b>						
<b>margetuximab</b> (HER2)	Breast (HER2+) "SOPHIA"					Green Cross (Korea only)
	Gastric (+anti-PD-1)					
<b>enoblituzumab</b> (B7-H3)	Solid Tum. (+anti-PD-1)					—
	Solid Tum. (monotherapy)					
<b>flotetuzumab</b> (CD123 x CD3)	AML/MDS					Servier (EU, Other)
<b>MGD007</b> (gpA33 x CD3)	Colorectal					—
<b>MGD009</b> (B7-H3 x CD3)	Solid Tumors					—
<b>MGA012</b> (PD-1)	Solid Tumors					Incyte <sup>(b)</sup>
<b>MGD013</b> (PD-1 x LAG-3)	Solid Tumors/Heme Mal.					—
<b>MGC018</b> (B7-H3) <sup>(a)</sup>	Solid Tumors					—
<b>MGD019</b> (PD-1 x CTLA-4)	Solid Tumors					—
<b>AUTOIMMUNE &amp; INFECTIOUS DISEASES</b>						
<b>teplizumab</b> (CD3)	Type 1 Diabetes Prev.					NIDDK/NIH
<b>MGD010</b> (CD32B x CD79B)	Autoimmune Disorders					—
<b>MGD014</b> (HIV x CD3)	HIV					NIAID/NIH

(a) ADC based on duocarmycin payload with cleavable peptide linker licensed from Synthron Biopharmaceuticals.

(b) MacroGenics retains rights to develop its pipeline assets in comb. w/MGA012 and manuf. portion of global clinical & commercial supply needs of MGA012.

DART    mAb    ADC

## MacroGenics' Antibody Formats

**DART and TRIDENT™** therapeutics enable the targeting of multiple antigens or cells with a single antibody-like molecule. Applications include the recruitment of a patient's T cells to destroy targeted cancer cells and the engagement of two checkpoint inhibitors for improved activation of the immune system. The flexibility of this platform allows for the design of molecules with increased half-life and valency compared to other multi-specific approaches.

**Fc-Optimized** antibodies mediate the killing of cancer cells through antibody-dependent cellular cytotoxicity, or ADCC, in which antibodies and immune cells cooperate to destroy targets such as tumor cells.

## Quick Facts

**Employees:**

324 (as of 10/18/17)

**Cash & Investments:**

\$244M at 6/30/17

(Excludes \$150M upfront from Incyte as part of MGA012 collaboration - expected to close 4Q17)

**Shares Outstanding:**

36.8M at 7/31/17

**Ticker:**

MGNX (NASDAQ)

**Locations:**

Rockville, MD

South San Francisco, CA

**Platforms:**

DART (bispecific)

TRIDENT (trispecific)

Fc Optimization

Cancer Stem-like Cells

## Key Collaborations

MacroGenics has developed significant alliances with leading pharmaceutical and biotechnology companies. Ongoing collaboration partners that have provided significant non-dilutive funding include:



October 2017



May 2016



September 2012



October 2010



October 2010

## Management

**Scott Koenig, M.D., Ph.D.**  
President and CEO

**James Karrels**  
SVP, CFO

**Ezio Bonvini, M.D.**  
SVP, Research and  
Chief Scientific Officer

**Eric Risser**  
SVP, Chief Business Officer

**Tom Spitznagel, Ph.D.**  
SVP, BioPharmaceutical  
Dev't and Manufacturing

**Jon Wigginton, M.D.**  
SVP, Clinical Development &  
Chief Medical Officer

**Syd Johnson, Ph.D.**  
VP, Antibody Engineering

**Paul Moore, Ph.D.**  
VP, Immunology &  
Cell Biology

**Jeffrey Peters**  
VP, Legal Affairs and  
Acting General Counsel

**James Vasselli, M.D.**  
VP, Clinical Research

## Board of Directors

**Paulo Costa (Chairman)**  
Former President & CEO,  
Novartis Pharmaceuticals, US

**Karen Ferrante, M.D.**  
Former CMO, Head of Rsch.,  
Tokai Pharmaceuticals

**Matthew Fust**  
Former CFO,  
Onyx Pharmaceuticals

**Kenneth Galbraith**  
General Partner,  
Five Corners Capital

**Edward Hurwitz**  
Managing Director,  
MPM Capital

**Scott Jackson**  
Former CEO,  
Celator Pharmaceuticals

**Scott Koenig, M.D., Ph.D.**  
President and CEO,  
MacroGenics

**David Stump, M.D.**  
Former EVP of R&D,  
Human Genome Sciences


## Monoclonal Antibodies in Clinical Development

### Margetuximab (HER2)

*Fc-optimized mAb*

*Phase 3*

Margetuximab is an Fc-optimized mAb that targets HER2-expressing tumors, including breast and gastroesophageal cancers. MacroGenics has engineered the Fc region of margetuximab to enhance its Fc-mediated effects, including improved ADCC. MacroGenics is conducting a Phase 3 registration trial (SOPHIA) in mBC patients to demonstrate clinical superiority to trastuzumab. The Company is also enrolling a Phase 1b/2 study for the treatment of advanced gastric cancer in combination with an anti-PD-1 agent.



### Enoblituzumab (B7-H3)

*Fc-optimized mAb*

*Phase 1b/2*

MacroGenics is developing a portfolio of first-in-class therapeutics that target B7-H3, a member of the B7 family of molecules involved in immune regulation and believed to inhibit T-cell activation. Enoblituzumab is an Fc-optimized monoclonal antibody that targets B7-H3 to take advantage of this antigen's broad expression across solid tumors. The Company is completing enrollment of monotherapy studies in patients with prostate, bladder and pediatric tumors. MacroGenics also continues to enroll patients in a combination study with anti-PD-1.

### MGA012 (PD-1)

*mAb*

*Phase 1*

MGA012 is a humanized, proprietary anti-PD-1 monoclonal antibody. In October 2017, MacroGenics entered into an exclusive global collaboration and license agreement with Incyte Corporation for MGA012, in which Incyte obtained exclusive worldwide rights for the development and commercialization of the molecule in all indications, while MacroGenics retains the right to develop its pipeline assets in combination with MGA012.

## DART Molecules in Clinical Development

Program (target)	Dev't Stage	Indications	Partner	MacroGenics' Rights
<b>Redirected T-Cell Killing:</b>				
<b>Flotetuzumab</b> (CD123 x CD3)	Phase 1	AML, MDS	Servier	North America, Japan, Korea, India
<b>MGD007</b> (gpA33 x CD3)	Phase 1	Colorectal cancer	Servier (option)	North America, Japan, Korea, India
<b>MGD009</b> (B7-H3 x CD3)	Phase 1	Solid tumors	—	Worldwide
<b>MGD014</b> (HIV x CD3)	IND Sub.	HIV	NIAID/NIH	Worldwide
<b>PF-06671008</b> (P-cadherin x CD3)	Phase 1	Solid tumors	Pfizer	Royalties and milestones
<b>Checkpoint Co-blockade:</b>				
<b>MGD013</b> (PD-1 x LAG-3)	Phase 1	Solid tumors, heme	—	Worldwide
<b>Signal Modulation:</b>				
<b>MGD010</b> (CD32B x CD79B)	Ph. 1 SAD completed	Autoimm. disord.	—	Worldwide